Tagged with novartis

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

Sandoz The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics.     Could you please give us a broad overview of the generics market in Argentina over the last decade? The dynamics of the generic…

Generics Cristina Campos, CPO Head and Country President of Novartis Portugal talks about the challenges surrounding market access in Portugal, as well as the affiliate’s strong investments in the country to help alleviate the economic burden that is faced by all companies here.  Between 2011 and 2012, the industry contributed €600…

CSR The President Director of Novartis Indonesia talks about the strong competition his company faces from local generics manufacturers, and his perspectives on the other challenges currently facing his company in the Indonesian market. You mentioned earlier that the current 20 percent growth of Novartis Indonesia is still possible because the…

UAE Walid Kattouha, Head of the Middle East Cluster of Novartis, speaks about why local knowledge is key to the company’s success, what have been and continues to be the major challenges for the company, and what the future looks like.   You are the leading pharmaceutical company in the Middle…

Novartis Healthcare Thomas Weigold, President & Managing Director of Novartis Healthcare Philippines expounds upon the rapidly developing healthcare system in the Philippines, what is yet left to improve upon and how Novartis is aiming to change the way people think about their health and their lifestyles. Mr. Weigold, you started heading the…

Novartis In our last meeting, you said that you were looking forward to a decade of continuous growth and to be the number one partner of choice for patients, physicians, governments and institutions. In what way have you been able to do that? Novartis Colombia has a broader portfolio compared to…

Novartis Belgium Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your way up the ladder. What attracted you to this industry and Novartis specifically? Prior to beginning my career as a…

Array   After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and Australia’s competitiveness for clinical trials in the Asian context. You arrived in July 2012 after working in different positions for…